Application of Imperatorin Angelicae Sinensis Extract in the Preparation of Drugs for the Treatment and / or Prevention of Infections Caused by Intracellular Bacteria
By regulating the immune function of host macrophages through purslane ester, the treatment of intracellular bacterial infections has been improved and the drug resistance problem has been solved in the existing technology, thus achieving effective inhibition of intracellular bacteria and ensuring the safety of host cells.
CN122297462APending Publication Date: 2026-06-30THE THIRD PEOPLES HOSPITAL OF SHENZHEN
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- THE THIRD PEOPLES HOSPITAL OF SHENZHEN
- Filing Date
- 2026-05-29
- Publication Date
- 2026-06-30
AI Technical Summary
Technical Problem
Existing direct-acting antimicrobial drugs have limited efficacy in treating intracellular bacterial infections, are prone to drug resistance, and may be toxic to host cells.
Method used
The immune function of host macrophages is regulated by using purslane ester to inhibit the survival of intracellular bacteria, rather than directly inhibiting bacterial growth. This enhances the ability to clear intracellular bacteria through host-directed therapy.
Benefits of technology
It effectively inhibits the survival of intracellular bacteria such as Mycobacterium tuberculosis, Mycobacterium abscessus, and Salmonella, reduces the risk of drug resistance, minimizes toxic effects on host cells, and provides a safe and effective treatment strategy.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure CN122297462A_ABST
Abstract
This application discloses the use of imperatorin angelica ester in the preparation of drugs for treating and / or preventing infections caused by intracellular bacteria, relating to the field of biomedical technology. The application includes administering an effective amount of imperatorin angelica ester to inhibit the survival of the intracellular bacteria within host macrophages. Imperatorin angelica ester specifically inhibits the survival and proliferation of intracellular bacteria (such as Mycobacterium tuberculosis, Mycobacterium abscessis, and Salmonella) within cells by modulating the immune function of host macrophages, such as enhancing their bactericidal activity or altering their intracellular microenvironment. This provides a new drug candidate and strategy for treating refractory intracellular bacterial infections, and also achieves beneficial effects such as enhancing host-directed antibacterial immunity, reducing toxic side effects, and minimizing potential drug resistance.
Need to check novelty before this filing date? Find Prior Art